Adverts

Open Access Articles- Top Results for Valrubicin

Valrubicin

</th></tr></th></tr>
Valrubicin
File:Valrubicin.svg
Systematic (IUPAC) name
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611021
  • US: C (Risk not ruled out)
  • (Prescription only)
Intravesical
Pharmacokinetic data
Bioavailability Negligible
Protein binding >99%
Metabolism Negligible
Excretion In urine
Identifiers
56124-62-0 7pxY
L01DB09
PubChem CID 454216
DrugBank DB00385 7pxY
ChemSpider 399974 7pxY
UNII 2C6NUM6878 7pxY
ChEMBL CHEMBL1096885 7pxY
Chemical data
Formula C34H36F3NO13
723.644 g/mol
 14pxY (what is this?)  (verify)

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues.[1] Valstar was relaunched on September 3, 2009.[2]

Side effects

References

  1. ^ "Manufacturing Issues Remain for Indevus' Valstar", U.S. Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008
  2. ^ "Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors" (Press release). 2009-09-03. Retrieved 2009-11-26.